Mis condolencias para la familia de Isabelle por su pérdida, y también pos
lo que supone que uno de nosotros haya fallecido.
Isabel
----- Original Message -----
From: "Miguel" <mcibrianarrakis@...>
To: "Mary Kearney" <drkearney@...>
Cc: "HispAtaxia" <HispAtaxia@yahoogroups.com>; "FA Babel-FAmily"
<FA_BabelFAmily@yahoogroups.com>
Sent: Monday, July 28, 2008 9:47 PM
Subject: RE: [FA_babelFAmily] Isabelle
> Lamento la muerte de Isabelle. Con mis abrazos a su familia, quiero
> trasmitirles mi mensaje de condolencia.
>
> Miguel-A. (paciente de ataxia de Friedreich).
> --------------------
>
> -----Mensaje original-----
> De: FA_babelFAmily@yahoogroups.com
> [mailto:FA_babelFAmily@yahoogroups.com]En nombre de Mary Kearney
> Enviado el: domingo, 27 de julio de 2008 23:07
> Para: FA_babelFAmily@yahoogroups.com
> Asunto: [FA_babelFAmily] Isabelle
>
>
> Hi
>
> I am sorry to hear of Isabelles death, Please convey my sympathy to
> Phillippe
>
>
> Mary Kearney Ireland
>
> ------------------------------------
>
> Yahoo! Groups Links
>
>
>
>
>
>
>
> ------------------------------------
>
> Yahoo! Groups Links
>
>
>
>
SRI International Research Team
Identifies Rare Sleep-Activated Neurons in the Cerebral Cortex
Findings May Have Important Implications for Treatment of Sleep Disorders
and for Understanding Mood and Memory
MENLO
PARK, CA -- (MARKET WIRE) -- 07/21/08 -- SRI International announced today that
a research team has identified the first example of neurons that are activated
in the cerebral cortex during slow wave sleep (SWS). The research, led by
Dmitry Gerashchenko and Thomas Kilduff, will be published in the Proceedings of
the National Academy of Sciences (PNAS) in a paper titled "Identification
of a Population of Sleep-Active Cerebral Cortex Neurons." The paper is
available via the PNAS Web site starting July 21.
The
presence of slow waves in the electroencephalogram (EEG) is the distinctive
"signature" of SWS and a type of activity that does not normally
occur during wakefulness. For years, researchers have hypothesized that
'slow-wave activity' (SWA) is correlated with the recuperative properties of
sleep and the brain's ability to learn, in part, because brain cells are
relatively quiet during this time. While populations of neurons activated
during sleep have been identified in the forebrain and the hypothalamus, up
until this point, neurons in the cortex have been seen as dormant. These new
results show that a group of rare neurons are active, rather than at rest,
during SWS.
"To
date, the role of the cortex in SWA has been a mystery since all cortical cells
were thought to be quiescent during SWS," said SRI's Dmitry Gerashchenko.
"We have discovered that the cortex not only plays a role, but harbors a
small population of neurons that is activated during spontaneous and catch-up
sleep, which occurs after sleep deprivation."
The
authors found that these neurons are active in the cortex of three species
(mice, rats and hamsters) during SWS. "Since these neurons also exist in
the human brain, they likely 'turn on' while we sleep as well," said SRI's
Thomas Kilduff, senior director of Neurobiology at SRI in whose laboratory at
SRI the work was conducted. Kilduff is also a consulting professor at Stanford
University School of Medicine. "As such, these neurons will be important
to study in sleep disorders such as insomnia. Activation of these cells during
sleep may have important implications for aspects of our behavior and cognitive
activities that depend heavily on sleep, such as our daytime performance,
memory and mood."
The
research also found that the type of neurons that are "turned on"
during sleep are the rarest of all currently known cortical neurons. These
cells express the enzyme neuronal nitric oxide synthase (nNOS) and thus make
nitric oxide (NO), which regulates blood flow in the brain and periphery.
A
notable feature of these results is that the proportion of nNOS neurons that
are activated seems to be related to the magnitude of homeostatic sleep drive;
that is, the longer animals are kept awake, the more nNOS neurons are activated
when the animals finally go to sleep. Additionally, nNOS neurons are the only
inhibitory cell type known to have long projections both within and between the
two hemispheres of the brain.
"The
next step will be to determine whether these neurons are the 'superhighway'
that conducts slow waves across the cortex during sleep," Kilduff
continued.
The
research was conducted by Dmitry Gerashchenko (SRI International), Jonathan P.
Wisor (SRI International), Deirdre Burns (SRI International), Rebecca K. Reh
(University of Washington), Priyattam J. Shiromani (West Roxbury VA Medical
Center and Harvard Medical School), Takeshi Sakurai (Kanazawa University),
Horacio O. de la Iglesia (University of Washington), and Thomas S. Kilduff (SRI
International and Stanford University School of Medicine).
The
research was supported by the National Heart, Lung and Blood Institute,
National Institute of Aging, National Institute of Mental Health, and the Sleep
Research Society Foundation.
Gerashchenko
presented the team's findings at the SLEEP 2008 symposium, "New
Developments in Sleep Research: Molecular Genetics, Gene Expression and Systems
Neurobiology" on Monday, June 9. For details on the symposium, visit: http://www.sleepmeeting.org/.
About
SRI International
Silicon
Valley-based SRI International (www.sri.com) is one of the world's leading independent research and
technology development organizations. Founded as Stanford Research Institute in
1946, SRI has been meeting the strategic needs of clients and partners for more
than 60 years. The nonprofit research institute performs client-sponsored research
and development for government agencies, businesses, and foundations. In
addition to conducting contract R&D, SRI licenses its technologies, forms
strategic partnerships, and creates spin-off companies.
Media
Contact:
Lindsay Sheppard
SRI International
(650) 859-2491
Genetic Information Nondiscrimination Act: 2007-2008
President Bush Signs Genetic Information Nondiscrimination Act of 2008
Washington, Wed., May 21 2008 — The President has signed into law the Genetic Information Nondiscrimination Act (GINA) that will protect Americans against discrimination based on their genetic information when it comes to health insurance and employment. The bill had passed the Senate unanimously and the House by a vote of 414 to 1. The long-awaited measure, which has been debated in Congress for 13 years, will pave the way for people to take full advantage of the promise of personalized medicine without fear of discrimination.
January 16, 2007: Referred to the Committee on Education and Labor, and in addition to the Committees on Energy and Commerce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
January 16, 2007: Referred to House Education and Labor
February 14, 2007: Committee Consideration and Mark-up Session Held
February 14, 2007: Ordered to be Reported (Amended) by Voice Vote
January 16, 2007: Referred to House Energy and Commerce
January 16, 2007: Referred to House Ways and Means
January 18, 2007: Referred to the Subcommittee on Health
March 5, 2007 at 3:47p.m.: Reported (Amended) by the Committee on Education and Labor. H. Rept. 110-28, Part I
March 5, 2007 at 3:48 p.m.: House Committee on Energy and Commerce Granted an extension for further consideration ending not later than March 23, 2007
March 5, 2007 at 3:49 p.m.: House Committee on Ways and Means Granted an extension for further consideration ending not later than March 23, 2007.
March 21, 2007: House committee/subcommittee actions: Ordered to be Reported (Amended) by Voice Vote
March 26, 2007: Reported (Amended) by the Committee on Ways and Means. H. Rept. 110-28, Part II.
March 29, 2007: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 110-28, Part III.
March 29, 2007: Placed on the Union Calendar, Calendar No. 46. The Union Calendar is the list of bills available for consideration to the Committee of the Whole. Bills are referred to the Union Calendar if they directly or indirectly deal with money.
April 25, 2007: House passes act.
2008
May 1, 2008:Introduced in House
May 1, 2008:Passed/agreed to in House: On motion to suspend the rules and agree to the resolution Agreed to by voice vote.
May 1, 2008:Passed/agreed to in Senate: Received in the Senate, considered, and agreed to without amendment by Unanimous Consent.
May 21, 2008: President Bush Signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008
January 22, 2007: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
January 31, 2007: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
March 29, 2007: Committee on Health, Education, Labor, and Pensions. Reported by Senator Kennedy with an amendment in the nature of a substitute. Without written report.
March 29, 2007: Placed on Senate Legislative Calendar under General Orders. Calendar No. 97.
April 10, 2007: By Senator Kennedy from Committee on Health, Education, Labor, and Pensions filed written report. Report No. 110-48
2008
April 24, 2008: Passed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 95 - 0. Record Vote Number: 113.
May 5, 2008: Resolving differences — House actions: On motion that the House agree to the Senate amendment Agreed to by the Yeas and Nays: 414 - 1 (Roll no. 234).
May 5, 2008: Cleared for White House.
May 21, 2008: President Bush Signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008
Un trial clinico cercherà di dimostrare l’efficacia di Algatrium Plus nei soggetti affetti da Atassia.
L’Associazione spagnola Ataxias en Movimiento (Atassie in Movimento) sta collaborando ad un trial clinico atto a ridurre lo stress ossidativo nei pazienti con atassia grazie all’apporto di Algatrium Plus, un’unica molecola specifica di DHA che si èdimostrata efficace nell’attivazione del sistema cellulare antiossidante.
Questo studio, iniziato la settimana scorsa, è mirato a dimostrare una riduzione del danno ossidativo in soggetti affetti da Atassia in modo che essi possano ottenere un trattamento con Algatrium Plus. Ventidue soggetti, principalmente con Atassia di Friedreich (18) e proporzionalmente altri quattro con altre forme di atassia stanno prendendo parte a questo trial. L’età dei partecipanti varia dai 20 ai 40 anni, ad ecccezione di una ragazza di 17 anni e due pazienti di 62 anni.Questo studio proseguirà per tre mesi; i partecipanti verranno sottoposti mediamente a tre analisi per valutare la diminuzione dello stress ossidativo. Algatrium Plus consiste in una sostanza sicura in quanto ha superato con successo le prime due fasi fondamentali, inclusa quella della mancanza di tossicità. Se al termine di questo periodo i risultati saranno quelli attesi, il trattamento continuerà in modo indefinitoe sarà disponibile per tutti i pazienti affetti da atassia. Secondo Isabel González dell’Associazione Ataxias en Movimiento: “Il punto principale è che una volta rivelati i risultati, una volta dimostrati i risultati positivi, le conclusioni verranno inoltrate alle autorità sanitarie e alle istituzioni in modo tale che Algatrium Plus possa essere fornito gratuitamente alle persone affette da questa patologia”. Joan Carles Domingo,chimico dell’Università di Barcellona e coordinatore di questo trial in qualità di ricercatore presso il dipartimento di ricerca di Brudy Technology, ha affermato: ”Entro tre mesi attendiamo una conferma della riduzione del danno ossidativo e a lungo andare un crollo in tutte le patologie correlate che possono colpire le persone affette da atassia, come il diabete o la perdita della visione periferica. Speriamo anche di osservare una riduzione nella gravità delle depressioni, spesso causate da malattie di questo genere”. Le atassie rappresentano una condizione caratterizzata da una perdita progressiva della coordinazione del movimento del corpo. Si tratta di un processo degenerativo altamente debilitante per il quale non esiste ancora un trattamento efficace. L’Associazione Ataxias en Movimiento sostiene una battaglia incessante per eradicare questa malattia e migliorare la qualità di vita delle persone colpite da questa patologia. Per Isabel González: ”Le atassie non hanno mai suscitato l’interesse dell’industria farmaceutica ma dopo aver ricevuto petizioni dai pazienti che stavano già assumendo Algatrium Plus per conto proprio abbiamo contattato i ricercatori della Brudy Technologyche ci hanno dimostrato il loro interesse per le malattie genetiche e, soprattutto, per portare avanti questo progetto”.
Note from babelFAmily:Daniela is an Italian patient with Friedreich’s ataxia, undergoing
treatment with Deferiprone (an iron chelator) and Lokomat (specialized physical
therapy).For more information, go
to the following link:
Message
from Daniela to Gian Piero Sommaruga, distributed with Daniela’s approval
From: Daniela
For: “gippi”
Sent on: Wednesday July 23, 20089:44 PM
Topic: Greetings
Hi Giampi,
First of all I would like to say hello, because vacation
time is approaching, and before long, I’ll be going off;besides, I wanted to keep you informed
about how it’s going for me.
Up to now I have been able to maintain the improvements I
made in the hospital, and I also have better truncal and neck posture, together
with better movements and coordination.
In some manual movements and some exercises, such asputting pegs in
holes and handling the Rubik’s cube, I have been able to do it faster and
more correctly.
My muscle mass has increased a little all over my body.
I have improved my standing posture when I am upright
with my weight on both legs, and also my voice is clearer.
Subject: [FA_babelFAmily] ENG: Putting Drug Development in Patients' Hands
Hello,
I found this interesting article, though not talking about the FA, ¡¡¡¡ we have too little presence in the media !!!!!!, I think that explains very well the importance of associations concerned and individual efforts to push forward in search of a cure.
I found this interesting article, though not talking about the FA, ¡¡¡¡ we have too little presence in the media !!!!!!, I think that explains very well the importance of associations concerned and individual efforts to push forward in search of a cure.
La morte di Isabelle è una grande perdita per tutti quelli che l'hanno conosciuta, le hanno voluto bene ed hanno condiviso con lei la lotta contro l'atassia.
Ammirevole esempio di forza.
Invio le mie personali condoglianze alla famiglia ed unisco la partecipazione dell'AISA (Associazione Italiana per la lotta alle Sindromi Atassiche).
Emis par Sylvie le: Sam 26 Juil 2008 à 20:13 Sujet du message: adieu à isabelle
bonjour tous
je reviens auprès de vous avec une bien triste nouvelle qui me bouleverse énormément... philippe hennebert vient de m'appeler pour m'annoncer qu'isabelle sa jeune épouse AF est décédée jeudi soir...
malgré la maladie isabelle rayonnait de joie de vivre... et elle avait trouvé l'amour de sa vie auprès de philippe pour qui elle était tout... ils étaient si beaux tous les deux...
isabelle de là où tu es j'espere que tu vois tous ceux qui t'aiment et que tu es en paix... philippe je fais l'impossible pour venir auprès de toi lundi dire adieu à isabelle, tu peux compter sur moi et sur mon amitié... tient bon mon ami... je suis déjà avec toi...
Lamento la muerte de Isabelle. Con mis abrazos a su familia, quiero
trasmitirles mi mensaje de condolencia.
Miguel-A. (paciente de ataxia de Friedreich).
--------------------
-----Mensaje original-----
De: FA_babelFAmily@yahoogroups.com
[mailto:FA_babelFAmily@yahoogroups.com]En nombre de Mary Kearney
Enviado el: domingo, 27 de julio de 2008 23:07
Para: FA_babelFAmily@yahoogroups.com
Asunto: [FA_babelFAmily] Isabelle
Hi
I am sorry to hear of Isabelles death, Please convey my sympathy to
Phillippe
Mary Kearney Ireland
------------------------------------
Yahoo! Groups Links
Un trial clinico cercherà di dimostrare l’efficacia di Algatrium Plus nei soggetti affetti da Atassia.
L’Associazione spagnola Ataxias en Movimiento (Atassie in Movimento) sta collaborando ad un trial clinico atto a ridurre lo stress ossidativo nei pazienti con atassia grazie all’apporto di Algatrium Plus, un’unica molecola specifica di DHA che si èdimostrata efficace nell’attivazione del sistema cellulare antiossidante.
Questo studio, iniziato la settimana scorsa, è mirato a dimostrare una riduzione del danno ossidativo in soggetti affetti da Atassia in modo che essi possano ottenere un trattamento con Algatrium Plus. Ventidue soggetti, principalmente con Atassia di Friedreich (18) e proporzionalmente altri quattro con altre forme di atassia stanno prendendo parte a questo trial. L’età dei partecipanti varia dai 20 ai 40 anni, ad ecccezione di una ragazza di 17 anni e due pazienti di 62 anni.Questo studio proseguirà per tre mesi; i partecipanti verranno sottoposti mediamente a tre analisi per valutare la diminuzione dello stress ossidativo. Algatrium Plus consiste in una sostanza sicura in quanto ha superato con successo le prime due fasi fondamentali, inclusa quella della mancanza di tossicità. Se al termine di questo periodo i risultati saranno quelli attesi, il trattamento continuerà in modo indefinitoe sarà disponibile per tutti i pazienti affetti da atassia. Secondo Isabel González dell’Associazione Ataxias en Movimiento: “Il punto principale è che una volta rivelati i risultati, una volta dimostrati i risultati positivi, le conclusioni verranno inoltrate alle autorità sanitarie e alle istituzioni in modo tale che Algatrium Plus possa essere fornito gratuitamente alle persone affette da questa patologia”. Joan Carles Domingo,chimico dell’Università di Barcellona e coordinatore di questo trial in qualità di ricercatore presso il dipartimento di ricerca di Brudy Technology, ha affermato: ”Entro tre mesi attendiamo una conferma della riduzione del danno ossidativo e a lungo andare un crollo in tutte le patologie correlate che possono colpire le persone affette da atassia, come il diabete o la perdita della visione periferica. Speriamo anche di osservare una riduzione nella gravità delle depressioni, spesso causate da malattie di questo genere”. Le atassie rappresentano una condizione caratterizzata da una perdita progressiva della coordinazione del movimento del corpo. Si tratta di un processo degenerativo altamente debilitante per il quale non esiste ancora un trattamento efficace. L’Associazione Ataxias en Movimiento sostiene una battaglia incessante per eradicare questa malattia e migliorare la qualità di vita delle persone colpite da questa patologia. Per Isabel González: ”Le atassie non hanno mai suscitato l’interesse dell’industria farmaceutica ma dopo aver ricevuto petizioni dai pazienti che stavano già assumendo Algatrium Plus per conto proprio abbiamo contattato i ricercatori della Brudy Technologyche ci hanno dimostrato il loro interesse per le malattie genetiche e, soprattutto, per portare avanti questo progetto”.
Note de babelFAmily: Daniela est une patiente Italienne AF qui suit une double thérapie: Ferriprox et Lokomat. Pour de plus amples informations, cliquez sur les liens suivants :
Avant tout, je veux te saluer parce que les vacances arrivent et d’ici peu je m’en vais et aussi pour te donner de mes nouvelles, te faire savoir comment je vais en ce moment.
A ce jour, j’ai réussi à conserver ce que j’ai acquis à l’hôpital, puis j’ai obtenu une meilleure position du tronc et du cou et également des améliorations dans les mains et pour quelques exercices comme planter des clous et faire tourner le rubicube, tout cela s’est amélioré et je le fais plus vite.
La masse musculaire a augmenté un peu dans tout le corps.
Je commence à obtenir une meilleure position quand je suis debout avec le poids du corps sur mes deux jambes et ma voix est également plus claire.
Australian scientists have made a key breakthrough in a rare disease that leaves children crippled and wheelchair-bound by their teens.
The Sydney research team has discovered what triggers Friedreich's ataxia, a degenerative disease that attacks the muscles, nervous system and heart of children and leads to an early death due to heart problems.
Well known New York-based Australian artist, Theresa Byrnes, 39, suffers from the disease.
The condition is caused by a build-up of toxic iron in the body's cells, and now a team from the University of Sydney understands why.
"Our study examines the actual reason for why the disease develops and demonstrates for the first time the processes responsible for the iron loading," said Des Richardson, a professor of cancer cell biology at the University of Sydney.
He said understanding toxic iron accumulation opened up the possibility of developing drug treatments that could remove it.
"In fact, using novel drugs that remove the toxic iron, we were able to demonstrate that they could prevent some heart complications in an animal model of Friedreich's ataxia."
The team is carrying out further studies to investigate the effectiveness of the new drugs in preventing the neurodegenerative aspect of the disease.
Friedreich's ataxia is a rare, genetically inherited disease that affects males and females equally, severely impacting their coordination and walking but not their mental capacity.
There is no known cure but the condition can be managed, often into a person's 50s, with orthopaedic appliances, physical therapy and medication for heart problems.
The findings are published in the US journal Proceedings of the National Academy of Sciences.
Key Mechanism Of Cellular Damage In Aging And Disease Discovered
ScienceDaily (July 26, 2008) — Researchers have taken a first snapshot of how a class of highly reactive molecules inflicts cellular damage as part of aging, heart disease, stroke, cancer, diabetes, kidney disease and Alzheimer's disease to name a few. According to a study published July 24 in the journal Cell, researchers have discovered a tool that can monitor related damage and determine the degree to which antioxidant drugs effectively combat disease.
Reactive oxygen species (ROS), which include free radicals, are highly reactive molecules that force change upon many molecules they encounter. The body uses ROS to signal for wound healing and to destroy invaders. Excess amounts, however, damage sensitive cell components, including proteins and DNA, in a process called oxidative stress. ROS are kept in check by the body's natural antioxidants, but when uncontrolled can lead to disease.
These highly reactive molecules are created as a side effect when structures within all human cells, the mitochondria, use oxygen to convert food into energy for life. Researchers once thought that altered mitochondrial function was important only in rare genetic diseases, but recent studies have revealed that oxidative stress plays a role in conditions that afflict many millions of patients. As a result, mitochondrial medicine is gaining momentum as groups like the Mitochondria Interest Group at the National Institutes of Health, professional societies and drug companies push basic science toward drug discovery.
"Our study provides a better glimpse of why a cell under assault by disease makes 10 times as many reactive oxygen species as the same cell when healthy," said Shey-ShingSheu, Ph.D., professor of Pharmacology and Physiology at the University of Rochester Medical Center, and a study author. "We have discovered a chemical tool for investigating how diseases cause damage, mitochondrion by mitochondrion, which should represent a tremendous advance as both a disease biomarker and for drug discovery."
Meltdown at the Powerhouse
The primary role of mitochondria is to convert food into chemical energy in the form of adenosine triphosphate (ATP), the molecule used by all human cells to store energy. To drive ATP production, electrons are passed along a series of enzymes, but a few "leak" during the process. Leaked electrons react with available oxygen to form the reactive oxygen species, termed superoxide. The emerging theory is that excess superoxide production causes the mitochondria to swell and rupture, resulting in a "cellular energy crisis" that ultimately leads to cell death in the many diseases of oxidative injury.
In the Cell study, researchers used a newly patented, protein-based probe to discover, and make visible, for the first time, fleeting bursts of superoxide production in mitochondria termed "superoxide flashes." The superoxide bursts oxidize cysteine residues in the probe, causing it to emit fluorescent light, which can then be detected and analyzed for patterns. Experiments not only identified superoxide flashes for the first time, but also confirmed that they exhibit a similar size and duration, regardless of the cell type they occur in. This uniform pattern of low-level superoxide production in the mitochondria of healthy cells is normal, perhaps keeping the ROS signaling system ready to fire, researchers said. The one quality of superoxide flashes found to vary was frequency, which dramatically increased during disease.
The research team looked at one kind of oxidative stress in particular: that caused when the oxygen supply to the heart is initially cut off (e.g. during a heart attack or stroke) and then re-established. When heart muscle cells were exposed to a non-oxygen solution for six hours, superoxide flash frequency decreased four-fold, to one event per 100 seconds. Upon re-introduction of oxygen, superoxide production increased eight-fold, confirming past work that re-oxygenation after a heart attack comes with a burst of destructive and uncontrolled superoxide production and oxidative stress.
Existing methods for measuring superoxide production involve chemical indicators or older protein probes, but these previous methods are not specific for superoxide, are damaged by light and provide a limited signal above background noise. The new probe is more sensitive, specific to superoxide, provides a stronger signal than other probes, and is the first to permit reversible measurements of superoxide levels on a millisecond timescale. The research team also created a genetically engineered mouse that expresses the probe within the mitochondria of all of its cells. These "superoxide mice" will enable researchers in the future to quantify the impact of uncontrolled mitochondrial superoxide production across many diseases.
Efforts to develop antioxidant drugs (e.g. vitamin E) to treat diseases of increased oxidative stress have met with limited success to date because they tried to eliminate ROS, rather than maintain the right amount, Sheu said. He established the Mitochondrial Research & Innovation Group (MRIG) at the MedicalCenter in 2002 with the goal of designing therapies to deliver precise amounts of antioxidants to the mitochondria of diseased cells only. MRIG teams are, for example, screening through compounds to confirm that oxidative stress can be reversed by mitochondria-specific drugs. The new superoxide flash probe will provide a powerful tool for determining the effectiveness of new classes of antioxidant drugs in reducing superoxide production at the right place and time.
The "birthday" for superoxide flashes came in June of 2003 in the lab of Robert Dirksen, Ph.D., associate professor of Pharmacology and Physiology at the MedicalCenter, when Linda Groom observed spontaneous bursts of fluorescent light using the newly developed protein-based superoxide indicator.
The current paper's lead author was Wang Wang, Ph.D. formerly a postdoctoral fellow at the National Institute on Aging at the National Institutes of Health. Aiwu Cheng, Jinhu Yin, Weidong Wang, Edward Lakatta and Mark Mattson also contributed from the NIH, as did Joseph Kao from the University of Maryland. Also contributing from PekingUniversity in Beijing were Huaqiang Fang, Wanrui Zhang, Jie Liu, Xianhua Wang, Kaitao Li, Peidong Han, Ming Zheng, and Heping Cheng, the corresponding author.
"One co-author on the current paper, Dr. Cheng of PekingUniversity, 15 years ago published a seminal study regarding local calcium release events, or calcium sparks," Dirksen said. "This study has been cited more than 900 times and has provided a major contribution to our understanding how the heart beats and why it fails. We believe that our serendipitous discovery of local mitochondrial superoxide flash events could be even more important because superoxide flash frequency may provide an accurate, real-time picture of how uncontrolled oxidative stress contributes to the progression of several, debilitating cardiovascular and neurological diseases."
Nota de babelFamily: Daniela es una paciente italiana con ataxia de Friedreich, en terapia con Ferriprox (quelantes de hierro) y Lokomat. Para más información, ir a los siguientes links:
Ante todo quería saludarte porque se acercan las vacaciones y dentro de poco tiempo me marcharé; además quería mantenerte informado sobre cómo me va.
Hasta hoy he conseguido mantener la mejoría adquirida en el hospital, además tengo mejor postura de tronco y cuello, unido a una mejoría de movimientos y coordinación. En algunos movimientos manuales y en algunos ejercicios como por ejemplo, manejar las figuras ensartables y rotar el cubo ruso, he conseguido hacerlo de forma más correcta y más rápida.
La masa muscular aumentó un poco en todo el cuerpo.
He mejorado la postura cuando estoy de pie con el peso sobre ambas piernas, y también la voz es más clara.
Nota de FA_babelFAmily: importante descubrimiento para combatir el insomnio. Dado que los enfermos de ataxia suelen presentar problemas de insomnio, hemos considerado que este descubrimiento científico puede ser de interés.
Cerebro- Halladas las neuronas responsables de la recuperación en fase dereposo.
Descubiertas las" neuronas del reposo", células de la corteza cerebral activadas sorprendentemente durante el sueño profundo – es decir, cuando el cerebro se recupera del cansancio del día - con una probable función restauradora para el cerebro. Estaobservación se debe a un estudio publicado por la Academia Americana de las Ciencias “PNAS”. “Hasta ahora”, explica a la ANSA Thomas Kilduff que dirige este estudio en la Facultad de Biociencias de Menlo Park en California, “se pensaba que las neuronas de la corteza se activaban solamente durante la fase REM del sueño, es decir, durante los sueños, pero que se desactivaban duranteel sueño profundo restaurador. Las neuronas activadas durante el sueño, llamadas nNOS, podrían tener un papel importante en la recuperación de funciones mentales que se regeneran durante el sueño profundo", opina Kilduff, el descubrimiento podría pues ser importante para el tratamiento del insomnio y en las perturbaciones del humor y de la memoria, debidos a la falta de sueño. El sueño profundo es la fase más importante de las horas que pasamos durmiendo porque es la fase durante la cual el cerebro se recupera. Cuanto más cansados estamos, más tiempo dura esta fase en la cual se registran ondas cortas en el cerebro. La amplitud de las ondas cortas depende a su vez del grado de cansancio. Anteriormente se pensaba que durante esta fase crucial del sueño, todas las neuronas de la corteza permanecían desactivadas. Pero los investigadores aislaron de la corteza cerebral dedistintos animales estapequeña familiade neuronas que se comportan de manera diferente, activándosejustamente durante el sueño profundo. Se trata de neuronas que producen óxido de nitrógeno (NO), un regulador natural del flujo de sangre en el cerebro, cuyo nombre es nNOS. Los expertos han comprobado incluso que el número de neuronas nNOS activadas en el sueño profundo es proporcional a laamplitud de las ondas cortas, es decir, al cansancio acumulado. Las nNOS podrían pues estar relacionadascon la producción de estas ondas reparadoras - supone Kilduff - o en cualquier caso con la función de estas mismas ondas. El hecho mismo de que las nNOSestén activadascuando se desactiva el resto de las neuronas de la corteza - concluyeKilduff - significa que desarrollan una función importante y nuestro próximo paso será ver qué ocurre si se interrumpe su actividad.”
Las células madre de la médula espinal podrían actuar como sistema de reparación nerviosa
Cultivadas en laboratorio y luego reimplantadas en el cuerpo, podrían conducir a tratamientos no quirúrgicos
(FUENTE: Massachusetts Institute of Technology, news release, July 21, 2008)
MARTES, 22 de julio (HealthDay News/Dr. Tango) -- Investigadores de EE. UU. y Suecia han identificado células madre adultas que podrían resultar valiosas en los esfuerzos por desarrollar tratamientos no quirúrgicos para las lesiones de la médula espinal. Señalaron que podría ser posible desarrollar medicamentos que mejoren la capacidad de estas células madre para reparar las células nerviosas dañadas. La médula espinal de un adulto contiene sólo un pequeño número de células madre, que proliferan despacio o en contadas veces y no promueven la regeneración por su propia cuenta. Pero algunas investigaciones han mostrado que las células madre de la médula espinal cultivadas en laboratorio y reimplantadas en el lugar de la lesión han restablecido algunas funciones físicas en roedores y primates paralíticos. En este nuevo estudio, científicos del Instituto Picower de aprendizaje y memoria del MIT en Cambridge, Massachusetts, y del Instituto Karolinska en Estocolmo hallaron que las células madre neurales en la médula espinal adulta están limitadas a una capa de células llamadas células ependimales, que conforman la membrana delgada que recubre los ventrículos en la parte interior del cerebro y la columna central que conecta con la médula espinal. "Hemos sido capaces de marcar genéticamente esta población de células madre neurales y luego dar seguimiento a su comportamiento. Hallamos que estas células proliferan después de una lesión en la médula espinal, migran hacia el lugar de la lesión y se diferencian varios meses después", dijo en un comunicado de prensa del MIT el autor del estudio Konstantinos Meletis. "La capacidad de las células ependimales para diferenciarse en varios tipos de células después de una lesión hace que sean muy interesantes desde el punto de vista de la intervención. Imagínese que pudiéramos regular el comportamiento de esta población de células madre para reparar células nerviosas dañadas", destacó Meletis. La investigación fue publicada en la edición de julio de PLoS Medicine.
Más información
El U.S. National Institute of Neurological Disorders and Stroke tiene más información sobre la lesión de médula espinal.
Emis par Sylvie le: Sam 26 Juil 2008 à 20:13 Sujet du message: adieu à isabelle
bonjour tous
je reviens auprès de vous avec une bien triste nouvelle qui me bouleverse énormément... philippe hennebert vient de m'appeler pour m'annoncer qu'isabelle sa jeune épouse AF est décédée jeudi soir...
malgré la maladie isabelle rayonnait de joie de vivre... et elle avait trouvé l'amour de sa vie auprès de philippe pour qui elle était tout... ils étaient si beaux tous les deux...
isabelle de là où tu es j'espere que tu vois tous ceux qui t'aiment et que tu es en paix... philippe je fais l'impossible pour venir auprès de toi lundi dire adieu à isabelle, tu peux compter sur moi et sur mon amitié... tient bon mon ami... je suis déjà avec toi...
Cuba Will Show in World Congress Advances in Genomic Medicine
Sat, 2008-07-19 04:48
Cuba’s achievements in the field of genomic medicine will be showed during the 3rd International Congress on Hereditary Ataxia that will take place in the eastern province of Holguin from October 1-3 later this year.
Specialists from Spain, Germany, Portugal, the United States, Mexico, Guatemala, and other Latin American countries, will participate in the meeting to discuss aspects related to therapiesfor the treatment of this disease.
Speaking to ACN, Dr. Luis Velásquez, Director of the Center for the Research and Rehabilitation from Hereditary Ataxias in Holguin, said that this disease affects 10 to 15% of the world population.
Among the countries with the highest rates are Mexico, India, Italy, Germany, Spain and the United States.
Velasquez said that the etiology of ataxias is still unknown but he said that there is a genetic damage or mutation in a group of this kind of disease. This transformation, he noted, produces an abnormal protein that causes the death of a group of structures of the nervous system.
Susie Davis was at a loss for words as she tried to express the gratitude that she felt for members of CommunityBaptistChurch on Thursday.
"It's like a big huge embrace from a loving family that I've never had before," Davis said after she found the words she was searching for.
The Henderson resident is one of about five families in Henderson who saw their homes worked on by other members of their community this week.
Tim Hobbs, the pastor at CommunityBaptistChurch, said that they usually plan a mission trip, but this year they wanted to help people in their own community.
"There are people here who need our help," he said.
This is the first year that the church has done this kind of mission work in the community, but Hobbs said he hopes that this is the start of something new.
Hobbs said this work is a part of fulfilling God's mission.
"It's up to us to give back," he said.
The church mission team began work on Monday and they've worked from about noon to 7 p.m. every day, church member Jica Crafton said.
Crafton said she liked seeing the progress that she and other church members have made on the houses they've worked on.
"Everything we've done has left a mark," she said.
Davis' house on Washington Street isn't the only house in Henderson that has seen renovations and upgrades. About 20 church members have worked on about five other sites painting, helping with yard work and staining decks.
"We don't deserve it," Davis said. "There are other people who need it."
Davis lives in her house with her son, Kevin Gentry.
"To sit and watch your property deteriorate is so painful," Davis said. "Especially when you've been the type who has done anything and everything."
Gentry was diagnosed with Friedreich's Ataxia, a genetic disorder that affects the nervous system, when he was 16 and Davis has been taking care of him since.
Davis said Gentry has defied the odds, and is a "miracle"-- doctors told her not to expect him to live past 21.
"If it wasn't for his church family he would have given up," she said.
Davis said that Community Baptist has been a huge help to her and her son.
Gentry, who is in a wheelchair, sat on his deck as it was being stained to visit with the church members.
"I think it's great that they take the time, not only for us, but for other people in the city," Gentry said.
Davis said she is so thankful for the work that she could sit and stare at her freshly painted garage all day.
"We're blessed to have a roof over our head and doubly blessed to have them do this work," Davis said.
MIT Identifies Cells For Spinal-Cord Repair - Could Lead
To Non-Surgical Treatment For Injuries
Article
Date: 23 Jul 2008 - 0:00 PDT
A
researcher at MIT's Picower Institute for Learning and Memory has pinpointed
stem cells within the spinal cord that, if persuaded to differentiate into more
healing cells and fewer scarring cells following an injury, may lead to a new,
non-surgical treatment for debilitating spinal-cord injuries.
The work, reported in the July issue of the journal PLoS (Public Library of Science) Biology, is by Konstantinos
Meletis, a postdoctoral fellow at the Picower Institute, and colleagues at the
Karolinska Institute in Sweden. Their results could lead to drugs that might
restore some degree of mobility to the 30,000 people worldwide afflicted each
year with spinal-cord injuries.
In a developing embryo, stem cells differentiate into all the specialized
tissues of the body. In adults, stem cells act as a repair system, replenishing
specialized cells, but also maintaining the normal turnover of regenerative organs
such as blood, skin or intestinal tissues.
The tiny number of stem cells in the adult spinal cord proliferate slowly or
rarely, and fail to promote regeneration on their own. But recent experiments
show that these same cells, grown in the lab and returned to the injury site,
can restore some function in paralyzed rodents and primates.
The researchers at MIT and the Karolinska Institute found that neural stem
cells in the adult spinal cord are limited to a layer of cube- or
column-shaped, cilia-covered cells called ependymal cells. These cells make up
the thin membrane lining the inner-brain ventricles and the connecting central
column of the spinal cord.
"We have been able to genetically mark this neural stem cell population
and then follow their behavior," Meletis said. "We find that these
cells proliferate upon spinal cord injury, migrate toward the injury site and
differentiate over several months."
The study uncovers the molecular mechanism underlying the tantalizing results
of the rodent and primate and goes one step further: By identifying for the
first time where this subpopulation of cells is found, they pave a path toward
manipulating them with drugs to boost their inborn ability to repair damaged
nerve cells.
"The ependymal cells' ability to turn into several different cell types
upon injury makes them very interesting from an intervention aspect: Imagine if
we could regulate the behavior of this stem cell population to repair damaged
nerve cells," Meletis said.
Upon injury, ependymal cells proliferate and migrate to the injured area,
producing a mass of scar-forming cells, plus fewer cells called
oligodendrocytes. The oligodendrocytes restore the myelin, or coating, on nerve
cells' long, slender, electrical impulse-carrying projections called axons.
Myelin is like the layer of plastic insulation on an electrical wire; without
it, nerve cells don't function properly.
"The limited functional recovery typically associated with central nervous
system injuries is in part due to the failure of severed axons to regrow and
reconnect with their target cells in the peripheral nervous system that extends
to our arms, hands, legs and feet," Meletis said. "The function of
axons that remain intact after injury in humans is often compromised without
insulating sheaths of myelin."
If scientists could genetically manipulate ependymal cells to produce more
myelin and less scar tissue after a spinal cord injury, they could potentially
avoid or reverse many of the debilitating effects of this type of injury, the
researchers said.
This study was supported by grants from the Swedish Research Council, the
Swedish Cancer Society, the Foundation for Strategic Research, the Karolinska
Institute, EuroStemCell and the Christopher and Dana Reeve Foundation.
AMERICHE - USA Studio: cellule staminali per riparare lesioni al midollo spinale
24 Luglio 2008
Ricercatori del MIT Picower Institute for Learning and Memory di Cambridge, Massachusetts, e del Karolinska Institute di Stoccolma rivelano che potrebbe essere possibile migliorare le lesioni alla spina dorsale usando le cellule staminali, e senza ricorrere ai bisturi. Gli scienziati hanno dichiarato, infatti, che potrebbe essere prodotto, nel futuro, un medicinale in grado di migliorare le possibilita' che hanno le cellule staminali di riparare i danni al sistema nervoso. Il midollo spinale di un adulto contiene solo un piccolo numero di cellule staminali, che si riproducono lentamente, sono molto rare e non si riproducono facilmente, ma la ricerca ha dimostrato che le cellule staminali del midollo possono riprodursi in laboratorio e inserendole nella lesione e' possibile ripristinare le funzioni paralizzate. L'esperimento e' stato testato su cavie e primati. Gli scienziati hanno scoperto che le cellule staminali neurali del midollo sono posizionate su cellule denominate ependimali. "Siamo stati in grado di marcare geneticamente queste cellule staminali neurali e di seguirne il comportamento. Abbiamo cosi' scoperto che si riproducono sulle lesioni al midollo spinale, migrano attraverso tutta la lesione e si "differenziano" nei mesi seguenti. L'abilita' delle cellule ependimali di trasformarsi in diverse cellule le rende interessanti. Immaginiamo, se si potesse controllarne il comportamento, di riparare cosi' i danni alle cellule nervose", ha dichiarato Konstantinos Meletis del MIT.
Experts At Anavex Offer A Primer On Promising 'Oxidative Stress' Theory
As trials on anti-amyloid vaccines continue to fail in the search for a viable Alzheimer's drug, a new approach - oxidative stress - is starting to emerge as a contender.
Anavex Life Sciences (AVXL.OB) is leading this promising avenue of research. It has developed an Alzheimer's drug candidate based on the theory that oxidative stress, not amyloid-beta plaques, is the cause of the disease. Oxidative stress is a type of damage to the body's tissues caused by the destructive action of certain forms of oxygen.
To help people better understand the science behind oxidative stress, Anavex offers this helpful primer:
What is Oxidative stress?
We are all familiar with processes like the rusting of iron, oil and butter turning rancid and fruits turning brown after prolonged exposure to air. All these phenomena are caused by exposure to oxygen in a process known as oxidation. Similar effects are known to happen inside our bodies in the molecular and cellular level, all because of the destructive action of a form of oxygen known as Reactive Oxygen Species (ROS). This destructive nature of oxygen comes in contrast to its unconditional necessity for the survival of all living aerobic organisms.
The term oxidative stress is used to describe a state in which the equilibrium between the production of ROS and the body's protective mechanisms (antioxidants and repair mechanisms) has been compromised, resulting in the oxidative damage of cells, tissues and organs. Moreover, ROS in the state of oxidative stress can impair several cellular signaling pathways that may result in the onset of age related diseases.
The Oxidative Stress And Alzheimer's Disease
A growing number of publications have supported the idea that oxidative stress may be the real cause of Alzheimer's. For example, in "Involvement of Oxidative Stress in Alzheimer's Disease," published in the Journal of Neuropathology and Experimental Neurology in 2006, study leader Dr. Akihiko Nunomura pointed to extensive evidence of mechanistic and chronological links between oxidative stress and a number of key characteristics of the disease.
Interestingly, this research also suggests that amyloid beta, which can act as an anti-oxidant, could in fact be initially produced by the body as it tries to combat the disease, only later turning toxic as the substance accumulates in large amounts. In other words, amyloid-beta could be the body's early protective reaction to the disease - suggesting that its removal from the brain during the early stages of Alzheimer's could in fact do more harm than good.
This theory is consistent with a number of factors for which the amyloid-beta hypothesis has been unable to account. There are reports, for instance, of individuals with amyloid-beta loads equivalent to Alzheimer's patients who do not suffer from the disease, as noted by R. J. Castellani et al in a 2006 article in the American Journal of Alzheimer's Disease and Other Dementias.
In addition, scientists have found a weak correlation between the amount of amyloid beta present in the brains of Alzheimer's sufferers and the severity of the illness. Furthermore, even though some test drugs reduce the amount of amyloid-beta in the brain, this is not correlated with substantial improvements in cognitive functioning.
Promising Pre-clinical Studies
Meanwhile, Anavex's alternative approach is showing great promise in early-stage testing. Anavex's drug candidate, known as ANAVEX 1-41, uses sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and repair cells compromised by its effects. In advanced pre-clinical studies, ANAVEX 1-41 appeared to provide neurons with potent protection from oxidative stress. It also prevented amyloid beta from becoming toxic and causing any follow-on damage. Moreover, ANAVEX 1-41 reduced memory deficits in animal test subjects - a particularly notable finding, given the quest for a drug that can actively reverse the effects of the disease.
A program of further work is currently underway to further assess the compound, including ongoing pre-clinical studies being carried out in collaboration with the Université Montpellier in France. The company is moving forward aggressively with this work, which is designed to pave the way for a rapid move towards human testing, expected to commence in late 2008 or early 2009.
While much still needs to be done, Anavex is enormously pleased with its progress to date on this promising new approach to combating one of the world's most complex and devastating diseases.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases such as Alzheimer's and depression. The company's proprietary SIGMACEPTOR™ Discovery Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. http://www.anavex.com
ANAVEX's SIGMACEPTOR™-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, etc.) The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties. The company believes that oxidative stress, not amyloid-beta, is the cause of Alzheimer's. ANAVEX 1-41, uses sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and repair cells compromised by its effects. So far, through the advanced pre-clinical phase of development, the compound has performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of this alternative approach to the disease.
ANAVEX SIGMACEPTOR™-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers such as colon, prostate, breast and lung. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.
Laufende Studien verunmöglichen CHMP-Prüfung unter Richtlinie für kleine Patientenpopulationen - Santhera erwartet negative Empfehlung für SNT-MC17/idebenone in Friedreich-Ataxie
Santhera Pharmaceuticals (SWX:SANN), ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, gibt heute bekannt, dass das Committee for Medicinal Products for Human Use (CHMP) der europäischen Arzneimittelbehörde (EMEA) Santhera informell darüber orientiert hat, dass die Zulassung von SNT-MC17/idebenone zur Behandlung der Friedreich-Ataxie zum heutigen Zeitpunkt keine positive Empfehlung erhalten wird. Gemäss diesen Informationen kann das Committee die Richtlinie für klinische Studien in kleinen Patientenpopulationen (Guideline on Clinical Trials in Small Populations) wegen den gut vorangehenden Phase-III-Studien nicht für den Antrag auf Marktzulassung anwenden. Santhera geht davon aus, dass das Medikament erst dann eine positive Empfehlung seitens des Committes erhalten kann, wenn die Resultate zumindest einer dieser beiden Studien vorliegen.
Resultate der klinischen Studien mit SNT-MC17/idebenone, welche die CHMP im Rahmen des Zulassungsverfahrens erhalten hat, zeigen statistisch und klinisch relevante Verbesserungen bei Friedreich-Ataxie-Patienten in alltäglichen Aktivitäten (Activities of Daily Living) sowie in kardiologischen und neurologischen Funktionen. In seinem Joint-Assessment-Bericht bestätigt das Committee, dass sowohl das Sicherheitsprofil, die präklinischen Daten als auch die technische Entwicklung von SNT-MC17/idebenone den Anforderungen für eine Zulassung entsprechen. Dennoch kommt die CHMP zum Schluss, dass die eingereichten Daten zum Wirkungs-/Risiko-Profil unter den üblichen klinischen Prüfrichtlinien nicht für eine Zulassung ausreichen. Der Antrag auf Marktzulassung basierte primär auf den positiven Daten der NICOSIA-Studie (NIH COllaboration with Santhera in Ataxia), einer gemeinsam mit den US National Institutes of Health durchgeführten klinischen Studie mit jugendlichen Friedreich-Ataxie-Patienten. Das Dossier umfasste neurologische und kardiologische Auswertungen dieser Daten sowie Resultate früherer, klinischer Studien seitens akademischer Forschungsinstitute, welche primär die positive Wirkung auf Erkrankungen des Herzmuskels (Kardiomyopathie) in einer breiteren Population aufgezeigt hatten.
"Die zum jetzigen Zeitpunkt mündlich kommunizierte negative Empfehlung der CHMP kommt überraschend und ist eine herbe Enttäuschung. Basierend auf früheren Gesprächen im Rahmen des Zulassungsprozesses hatten wir erwartet, dass unser Dossier unter der Richtlinie für klinische Versuche in kleinen Patientenpopulationen geprüft wird", erklärt Klaus Schollmeier, Chief Executive Officer von Santhera. "Als wir den Antrag auf Marktzulassung stellten, lief die Patientenrekrutierung unserer europäischen Phase-III-Studie MICONOS nur schleppend, weshalb wir über die Wahrscheinlichkeit eines erfolgreichen Abschlusses innerhalb eines vernünftigen Zeitrahmens eher besorgt waren. Zu diesem Zeitpunkt war darüber hinaus unsere Phase-III-Studie IONIA in den USA noch nicht gestartet. Wir haben die CHMP laufend über den Status der beiden Studien informiert. Jetzt scheint es, dass sich unser Erfolg, dennoch in der Lage zu sein, weitere Daten zu erheben, gegen uns wendet. Zusammen mit unserem Partner Takeda werden wir nun mögliche Optionen prüfen, damit SNT-MC17/idebenone in Europa so bald als möglich als kontrolliertes pharmazeutisches Produkt zur Behandlung der Friedreichs-Ataxie eingesetzt werden kann."
Die EMEA verfügt über einen formalen Prozess, unter welchem ein Unternehmen Einsprache zu einer negativen CHMP-Empfehlung erheben und eine weitere Prüfung durch ein gesondertes wissenschaftliches Gremium (Scientific Advisory Group) verlangen kann. In einem solchen Fall könnte eine abschliessende Empfehlung innerhalb von sechs Monaten vorliegen. Santhera und Marketingpartner Takeda werden diese Möglichkeit sorgfältig prüfen. Sollte diese Option verfolgt werden, gilt eine 15-tägige Einsprachefrist nach offiziellem Erhalt der CHMP-Empfehlung.
Status der laufenden Phase-III-Studien
In Europa sind rund 90 % der für die Phase-III-Studie namens MICONOS (Mitochondrial Protection With Idebenone In Cardiological Or Neurological Outcome Study) notwendigen Patienten rekrutiert. Bis Ende Jahr sollte die Rekrutierung abgeschlossen sein.
In den USA sind bereits 41 Patienten in die Phase-III-Studie namens IONIA (Idebenone effects On Neurological ICARS Assessments) eingeschlossen. Santhera hat sich letztes Jahr mit der US Food and Drug Administration unter einem Special Protocol Assessment darauf geeinigt, mindestens 51 Patienten zu rekrutieren und, falls möglich, noch weitere Patienten einzuschliessen. Aufgrund der aktuellen Aussicht auf weitere Studienteilnehmer erwarten Santhera und die US-Studienleiter, dass die Studie schlussendlich zwischen 60 und 65 Patienten umfassen wird.
Überblick über die Pipeline und finanzieller Ausblick
Santhera wird anlässlich der für 22. August 2008 geplanten Publikation des Halbjahresberichts 2008 über den Status der gesamten klinischen Pipeline und die finanziellen Kennzahlen informieren.
Conference call
At 19.00 CET / 18.00 UKT / 13.00 EST on July 24, 2008, Santhera will host a conference call (in English only). Anyone interested in participating may join the teleconference facility using the following dial-in in Switzerland +41 52 267 07 36. The conference call will be recorded for playback and is available one hour after the conference call ends and for 20 days under +41 52 267 07 00 (reference no. 668713).
The Company was informed by the CHMP at 18:36 CET and acknowledges the late-breaking nature of this news. Management will be available after the call as well as all day Friday to respond to questions from anyone who missed the opportunity to participate in the live teleconference conference.
Über Friedreich-Ataxie
Friedreich-Ataxie ist eine seltene, aber schwere, genetisch bedingte neuromuskuläre Erkrankung, die zur Degeneration von Nerven- und Muskelgewebe führt. Diese Krankheit führt zum Verlust von Muskelkontrolle, zu unkoordinierten Bewegungen, zu Muskelschwund und zur Verdickung der Herzwände. Aus diesem Grund beträgt die durchschnittliche Lebenserwartung von Friedreich-Ataxie-Patienten lediglich ungefähr 35 bis 50 Jahre. Friedreich-Ataxie betrifft die männliche und weibliche kaukasische Bevölkerung gleichermassen. In Nordamerika und Europa sind schätzungsweise 20'000 Patienten von der Krankheit betroffen.
Friedreich-Ataxie wird durch einen genetischen Defekt in dem für Frataxin kodierenden Gen verursacht. Geringere Mengen dieses Proteins führen letztlich zu einer Beeinträchtigung der Energieproduktion in den Mitochondrien, den Energieproduzenten der Zellen sowie zu einer Erhöhung von oxidativem Stress. Primär durch den Frataxin-Mangel betroffen sind die Gewebe mit dem höchsten Energiebedarf, insbesondere Nerven- und Herzgewebe, was zu pathologischen Veränderungen in der Herzmuskelanatomie und -funktion sowie zum Verlust von Nervenzellen führt.
* * *
Über Santhera
Santhera Pharmaceuticals (SWX:SANN) ist ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, das sich auf die Erforschung, die Entwicklung und die Vermarktung von niedermolekularen Medikamenten spezialisiert hat. Santhera prüft zurzeit drei Wirkstoffe in fünf klinischen Entwicklungsprogrammen. Das erste Produkt, SNT-MC17 (INN: idebenone), hat in Kanada die bedingte Marktzulassung zur Behandlung von Friedreich-Ataxie erhalten und wird in unter dem Produktnamen Catena® vermarktet. Das Medikament wird zurzeit auch von den Gesundheitsbehörden in der EU und der Schweiz geprüft und befindet sich in den USA in der Zulassungsstudie. Der Wirkstoff hat auch positive Wirkung in Duchenne-Muskeldystrophie, einer zweiten Indikation gezeigt. Weitere Informationen zu Santhera finden Sie unter www.santhera.com.
Für weitere Auskünfte wenden Sie sich bitte an:
Klaus Schollmeier, Chief Executive Officer
Telefon +41 (0)61 906 89 52
klaus.schollmeier@...
Barbara Heller, Chief Financial Officer
Telefon +41 (0)61 906 89 54
barbara.heller@...
Thomas Staffelbach, Head Public & Investor Relations
Telefon +41 (0)61 906 89 47
thomas.staffelbach@...
Disclaimer / Zukunftsgerichtete Aussagen
Diese Publikation stellt kein Angebot oder Einladung dar, um Wertschriften von Santhera Pharmaceuticals Holding AG zu erwerben oder zu zeichnen. Diese Veröffentlichung kann gewisse in die Zukunft gerichtete Aussagen über Santhera und ihre Geschäftsaktivitäten enthalten. Solche Aussagen beinhalten gewisse Risiken, Unsicherheiten und andere Faktoren, die zur Folge haben können, dass tatsächlich erzielte Geschäftsresultate, finanzielle Verfassung, Leistungsfähigkeit und Zielerreichung wesentlich von dem abweichen, was in solchen Aussagen implizit oder explizit erwähnt ist. Leserinnen und Leser sollten diesen Aussagen daher kein übermässiges Gewicht beimessen; dies ganz besonders nicht im Zusammenhang mit Verträgen oder Investitionsentscheiden. Santhera übernimmt keine Verpflichtung, diese in die Zukunft gerichteten Aussagen zu aktualisieren.
Diese Mitteilung ist eine Übersetzung der verbindlichen englischen Originalversion.
Santhera's Ongoing Studies Prevent CHMP Review under Small Patient Populations Guideline - Company Expects Negative CHMP Opinion on MAA for SNT-MC17/Idebenone in Friedreich's Ataxia
Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has informally advised Santhera that it would not support a positive opinion for the Marketing Authorization Application (MAA) for SNT-MC17/idebenone to treat patients with Friedreich's Ataxia at this time. According to the information received, Santhera's ongoing phase III trials prevented the CHMP from reviewing the Company's application under the EMEA Guideline on Clinical Trials in Small Populations as requested by Santhera in its MAA filing. The Company's understanding is that the Committee believes it cannot approve the drug before data from at least one of Santhera's advanced phase III clinical programs in Europe and the United States are submitted for review.
In clinical studies submitted to the CHMP as part of the approval process, SNT-MC17/idebenone showed statistically and clinically relevant improvements in Friedreich's Ataxia patients, as measured by Activities of Daily Living scores as well as in cardiac and neurological functions. The CHMP Joint Assessment Report supports the safety profile, preclinical data and technical development of SNT-MC17/idebenone as sufficient to potentially meet its criteria for approval. However, the CHMP concluded that Santhera had not submitted a sufficient set of data demonstrating a clear positive risk/benefit balance for approval under the Committee's standard clinical review guidelines. The MAA filing was based primarily on positive pediatric data generated in the NICOSIA (NIH COllaboration with Santhera in Ataxia) study, a collaborative trial with the US National Institutes of Health, analyzing a variety of neurological and cardiac outcome measures and was supported by evidence from several academic trials in a wider population that demonstrated efficacy in the treatment of cardiac hypertrophy in Friedreich's Ataxia patients.
Klaus Schollmeier, Chief Executive Officer of Santhera, commented: "The possible negative CHMP opinion is obviously disappointing and surprising as well. Based on earlier discussions, we had expected to qualify for the EMEA Guideline on Clinical Trials in Small Populations. When we submitted the MAA, our European phase III clinical trial MICONOS was running, but we were very concerned about our enrollment prospects. At that time, our US phase III trial IONIA had not even yet started. We kept the Committee informed about the status of both trials throughout the MAA filing process. It seems that our success in gathering additional data has been working against us. Together with our partner Takeda, we will evaluate our options for making SNT-MC17/idebenone available as a controlled pharmaceutical product to Friedreich's Ataxia patients in Europe as soon as feasible".
The EMEA has a formal process whereby the MAA sponsor may request reexamination of the CHMP's initial negative opinion, including a review of the dossier by an independent specialist Scientific Advisory Group. If Santhera requests such a review, a final opinion could be rendered within approximately six months. Santhera together with its marketing partner Takeda are evaluating this option carefully. If this alternative is pursued, the appeal must be submitted within the next 15 days from the official CHMP opinion.
Update on ongoing Phase III clinical trials
In Europe, the MICONOS (Mitochondrial Protection With Idebenone In Cardiological Or Neurological Outcome Study) phase III trial has currently enrolled approximately 90% of the patients needed to complete recruitment and is on track for full enrollment by the end of 2008.
Santhera will provide information on the status of its entire development pipeline and to update on financial guidance as part of its Half-Year Financial Results Report on August, 22, 2008.
Conference call
At 19.00 CET / 18.00 UKT / 13.00 EST on July 24, 2008, Santhera will host a conference call. People interested in participating may join the teleconference facility using the following dial-in in Switzerland +41 52 267 07 36. The conference call will be recorded for playback and is available one hour after the conference call ends and for 20 days under +41 52 267 07 00 (reference no. 668713).
The Company was informed by the CHMP at 18:36 CET and acknowledges the late-breaking nature of this news. Management will be available after the call as well as all day Friday to respond to questions from anyone who missed the opportunity to participate in the live teleconference conference.
About Friedreich's Ataxia
Friedreich's Ataxia is a rare but severe genetic neuromuscular disorder that results in the degeneration of an individual's nerve and muscle tissue. This disorder causes loss of muscle control, uncoordinated movements, muscle wasting and thickening of heart walls which frequently leads to a shortened life span. Friedreich's Ataxia affects both Caucasian males and females equally and it is estimated that about 20,000 patients suffer from the disease in both North America and Europe. Average life expectancy for Friedreich's Ataxia patients is limited to approximately 35 to 50 years.
The disorder results from a genetic defect in the gene encoding for frataxin. Reduced levels of this protein ultimately result in impaired energy production in mitochondria, the cells' energy production centers, and elevated oxidative stress. Tissues that have the highest need for energy, in particular nerve and cardiac tissues, are primarily affected by frataxin deficiency resulting in pathological changes in heart muscle anatomy and function and loss of nerve cells.
* * *
About Santhera
Santhera Pharmaceuticals (SWX: SANN) is a Swiss specialty pharmaceutical company focused on the discovery, development and marketing of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera currently investigates three compounds in five clinical-stage development programs. The Company's first product, SNT-MC17 (INN: idebenone), has received a marketing approval with conditions from Health Canada to treat Friedreich's Ataxia and will be marketed under its brand name Catena®. The product is also under review by health authorities in the EU and in Switzerland, while in the United States, a pivotal phase III trial is recruiting patients. SNT-MC17/idebenone has also shown efficacy in a phase II clinical trial as a potential treatment for the indication Duchenne Muscular Dystrophy. For further information, please visit www.santhera.com.
For Further Information, Contact
Klaus Schollmeier, Chief Executive Officer
Phone: +41 (0)61 906 89 52
klaus.schollmeier@...
Barbara Heller, Chief Financial Officer
Phone: +41 (0)61 906 89 54
barbara.heller@...
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@...
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements.
AUB
adopts accommodating attitude toward students with disabilities
Daily Star staff Thursday,
July 24, 2008
BEIRUT: For FawziYassin, who graduated this year with a degree in
computer science, academic standards were not his only motivation for choosing
to study at the American University of Beirut (AUB) - an accommodating
attitude was a high priority.
Fawzi
is one of at least a dozen disabled students who graduated from AUB over the
past decade. But he was the only one this year who rolled on his wheelchair to
receive his degree from then-President John Waterbury
during the June commencement exercises.
Stricken
with a debilitating genetic disease - Friedreich's ataxia - that damages
the nervous system and leaves its victims with impaired mobility as well as other symptoms, Fawzi
needed a university that could provide him with easy access to classes. While AUB's 150-year-old, hilly campus is not ideal to a
wheel-chair-bound individual, the university's administration was eager to
accommodate its prospective student.
So when Fawzi applied in 2005, the Faculty of Arts and Sciences
promised to reschedule any classes that proved inaccessible to him. A year
later, the Protection Office bought a wheel-chair accessible car to transport disabled students
along with their wheel chairs across campus, and
particularly from upper to lower campus and vice versa.
While AUB
does not receive many disabled students every year, it has a policy to equip
all new buildings with ramps and disabled-friendly bathrooms. As for the old
buildings, they are gradually being provided with disabled access. "We are
very keen to make our disabled student population feel comfortable and at
home," said Dean of Student Affairs MarounKisirwani.
Disabled students who wish to study at AUB may also benefit from the Women's
League Scholarship Fund for Handicapped Students, which was established in 1999. Several disabled
students were awarded financial assistance from this scholarship fund. During
the academic year 2005-06, the recipient was FawziYassin.
The Red
Cross Youth club at AUB also offers services to students with special needs,
helping them around campus and with their studies through the 25-year-old Room
for Visually-Challenged Students, which is jointly run with the Office of
Student Affairs. The room offers a variety of services, such as turning books
into audio tracks, through a computer software or
student volunteers, and an archive of taped university text books. "Our
volunteers also read for visually-impaired students and help them with their
online and library searches," said RayyaFallis, the president of the Red Cross AUB Youth Club.
Fawzi's
experience at AUB changed his perspective on life. Before joining the
university, he saw his world as confined to his parents' home, with no prospects
for a future. Now, he plans to enroll in a master's
program at AUB and work part-time.
"Before
joining AUB, I did not think of going to work, and thought I would live at home
forever. Now I have lots of hope for the future," he said. "AUB built
my personality and allowed me to make lots of friends. I am so thankful for
that opportunity and would like to tell people: Never to lose hope. Always keep
your eye on the goal and don't think it's impossible." - TheDaily Star
KyotoU. centers to provide ES-derived cells The Yomiuri Shimbun
Kyoto University and some research centers will launch a project this year to provide institutions with nerve cells grown from human embryo-stem (ES) cells, The Yomiuri Shimbun has learned.
The project is expected to help accelerate new drug development and research into the causes of neurological disorders, including Alzheimer's, Lou Gehrig's disease and Huntington's disease.
As part of the project, researchers will implant specific types of genes, known to cause neurological diseases, into human ES cells. Researchers will make the ES cells, which can be transformed into various types of cells, grow into neurons, which they will then provide to research centers for study.
As part of its research into Alzheimer's, a team including Kyoto University Prof. Norio Nakatsuji has succeeded in introducing a causative gene into human ES cells.
Messaggio diffuso con l’autorizzazione di Daniela.
From: Daniela
To: "gippi"
Sent: Wednesday, July 23, 20089:44 PM
Subject: Saluti
Ciao Giampi,
innanzi tutto volevo salutarti perchè si avvicinano le vacanze e fra poco parto e poi per raccontarti le news di come sto andando. Ad oggi sono riuscita a mantenere quello che avevo acquisito in ospedale, poi ho ottenuto una posizione migliore con il tronco e con il collo e anche nei movimenti e nella coordinazione. Inoltre in alcuni movimenti manuali e in alcuni esercizi come infilare i chiodini e roteare il cubo russo sono diventata più corretta e più veloce.
La massa muscolare è aumentata un po' in tutto il corpo.
Ho incominciato a ottenere una posizione più corretta quando sto in piedi portando il carico su entrambe le gambe e anche la voce è piu' chiara. A risentirci a presto e buone vacanze. Dany